Cours Nivalis Therapeutics Inc Nasdaq
Actions
US65481J1097
Recherche biotechnologique et médicale
CA 2024 * | 17,64 M 16,04 M | CA 2025 * | 20,2 M 18,37 M | Capitalisation | 4,46 Md 4,05 Md |
---|---|---|---|---|---|
Résultat net 2024 * | -97 M -88,2 M | Résultat net 2025 * | -110 M -100 M | VE / CA 2024 * | 239 x |
Trésorerie nette 2024 * | 233 M 212 M | Trésorerie nette 2025 * | 208 M 189 M | VE / CA 2025 * | 210 x |
PER 2024 * |
-49,2
x | PER 2025 * |
-37
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 95,35% |
Dernier transcript sur Nivalis Therapeutics Inc
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Mitchell Gold
CEO | Chief Executive Officer | 57 | 24/07/17 |
Director of Finance/CFO | - | 01/06/17 | |
Stanford Peng
PSD | President | 53 | 24/07/17 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Robert Conway
BRD | Director/Board Member | 70 | 01/07/17 |
Mitchell Gold
CEO | Chief Executive Officer | 57 | 24/07/17 |
James Topper
BRD | Director/Board Member | 62 | 01/06/16 |
Varia. 1 janv. | Capi. | |
---|---|---|
+9,42% | 115 Md | |
+11,84% | 106 Md | |
-1,05% | 21,96 Md | |
-14,15% | 21,87 Md | |
-5,29% | 19,21 Md | |
-4,16% | 18,08 Md | |
-38,29% | 17,71 Md | |
+7,99% | 14,32 Md | |
+36,24% | 12,42 Md |